Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 25,172 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Epilepsy in Children, Pharmaco-Resistant Epilepsy
Interventions: Not listed
Lead sponsor: Senda Biosciences; Industry
Eligibility: 1 Year to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bullying
Interventions: STAC Parent Module for Middle School; Behavioral
Lead sponsor: Boise State University; Other
Eligibility: 21 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
Interventions: TAK-500, Pembrolizumab, Tocilizumab, Dexamethasone; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more

Conditions: Relapsed and Refractory Multiple Myeloma (RRMM)
Interventions: Non-Interventional; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Activin ligand-trap biological therapy, Placebo, Normal Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Antioxidant, Placebo; Dietary Supplement · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Select Advanced Solid Tumors
Interventions: Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2041
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kidney Diseases, Kidney Failure, Chronic, Diabetic Nephropathy, Lupus Nephritis, Glomerulonephritis, IGA
Interventions: Not listed
Lead sponsor: The Rogosin Institute; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Vaccine-Preventable Diseases, COVID-19 Pandemic, Health-Related Behavior, Health Knowledge, Attitudes, Practice, Narration
Interventions: Baseline surveys, Digital Storytelling Intervention, Information Control Intervention; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Prediabetic State, Obesity, Gestational Diabetes
Interventions: Presessions, National Diabetes Prevention Program; Behavioral
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 483 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Biliary Cancer
Interventions: Gemcitabine, docetaxel, and capecitabine; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Embolism
Interventions: Contrast-enhanced chest CT; Diagnostic Test
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Biospecimen Collection, Counseling, Educational Intervention, Electronic Health Record Review, Medical Device Usage and Evaluation, Questionnaire Administration; Procedure · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Solid Tumor
Interventions: [18F]FLT-PET/CT; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 8 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT; Drug · Other
Lead sponsor: Hearn Jay Cho; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Parkinson Disease
Interventions: Procedure/Surgery: Response Inhibition and Deep Brain Stimulation in Parkinson's disease; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Urticaria
Interventions: TEV-45779, XOLAIR® Injection; Combination Product
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Bakersfield, California • Clearwater, Florida • Coral Gables, Florida + 6 more

Conditions: Aphakia, Cataract, Presbyopia
Interventions: Light Adjustable lens (LAL) and Light Delivery Device (LDD) - Pre-COVID Population, SofPort LI61AO IOL, Tecnis ZCB00 or ZTC150 IOL; Device
Lead sponsor: RxSight, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Infertility
Interventions: Day 3 embryo transfer, Day 2 embryo transfer; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: Chromoendoscopy with magnification; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Crohn's Disease
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Lymphoma Cancer, Gynecological Cancers
Interventions: group intervention and questionnaires, individual phone intervention and questionnaires, expressive writing (arm will not be include in the randomization); Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 70 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Alzheimer's Disease Prevention
Interventions: Aerobic vs. Non-Aerobic exercise; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Healthy
Interventions: Rosuvastatin, Clopidogrel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Comparison of Microbiome Composition and Biomarkers in Pharmaco Resistant and Pharmaco-Sensitive Epilepsy

Middle School Parent Module for a Brief Bullying Intervention Program

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)

Racial and Aging Effects of Acute Antioxidant Supplementation

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents

Presessions for the National Diabetes Prevention Program

GTX Regimen for Biliary Cancers

Quantitative 3-Dimensional Chest CT Vascular Reconstruction Before and After Anticoagulation for Pulmonary Embolism

Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients

Evaluation of [18F]FLT PET/CT as an Early Predictor of Outcome in Pediatric Solid Tumors

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

Investigating Inhibitory Control Networks in Parkinson's Disease

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

A Clinical Study to Evaluate The Safety and Effectiveness of The RxSight Light Adjustable Lens (LAL) In Subjects Desiring an Extended Depth of Focus

Day of Embryo Transfer for Patients Undergoing In Vitro Fertilization

Chromoendoscopy for Ulcerative Colitis Surveillance

Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography

A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer

Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study

Drug Interaction Study of Clopidogrel and Rosuvastatin